Reduced soluble CD14 levels after switching from a dual regimen with lamivudine plus boosted protease inhibitors to lamivudine plus dolutegravir in virologically suppressed HIV-infected patients

Reduced soluble CD14 levels after switching from a dual regimen with lamivudine plus boosted protease inhibitors to lamivudine plus dolutegravir in virologically suppressed HIV-infected patients

Background: HIV-induced systemic immune activation and inflammation have been associated with morbidity and mortality in virologically suppressed patients. Objective: To evaluate the impact of treatment switch from a dual regimen with lamivudine (3TC) plus ritonavir-boosted protease inhibitors (PI/r...

Full description

Bibliographic Details
Main Authors: Francesca Lombardi, Simone Belmonti, Alberto Borghetti, Arturo Ciccullo, Gianmaria Baldin, Roberto Cauda, Massimiliano Fabbiani, Simona Di Giambenedetto
Format: Article
Language:English
Published: Taylor & Francis Group 2019-05-01
Series:HIV Research & Clinical Practice
Subjects:
hiv
inflammation
inflammatory biomarkers
dual therapy
dolutegravir
scd14
Online Access:http://dx.doi.org/10.1080/25787489.2019.1653512

Internet

http://dx.doi.org/10.1080/25787489.2019.1653512

Similar Items